Treatment Options for Metaplastic Breast Cancer
Joint Authors
Shah, Dhruvil R.
Martinez, Steve R.
Tseng, Warren H.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-06-21
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Metaplastic breast cancer (MBC) is a malignancy characterized by the histologic presence of two or more cellular types, commonly a mixture of epithelial and mesenchymal components.
MBC is rare relative to invasive ductal carcinoma (IDC), representing less than 1% of all breast cancers.
Other than a lower rate of lymph node metastases, MBC tumors display poorer prognostic features relative to IDC.
Due to its low incidence and pathological variability, the ideal treatment paradigm for MBC is unknown.
Because of its rarity, MBC has been treated as a variant of IDC.
Despite similar treatment regimens, however, patients with MBC have worse outcomes.
Recent research is focused on biological differences between MBC and IDC and potential novel targets for chemotherapeutic agents.
This paper serves as a summation of current literature on approaches to the multidisciplinary treatment of patients with MBC.
American Psychological Association (APA)
Shah, Dhruvil R.& Tseng, Warren H.& Martinez, Steve R.. 2012. Treatment Options for Metaplastic Breast Cancer. ISRN Oncology،Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-492075
Modern Language Association (MLA)
Shah, Dhruvil R.…[et al.]. Treatment Options for Metaplastic Breast Cancer. ISRN Oncology No. 2012 (2012), pp.1-4.
https://search.emarefa.net/detail/BIM-492075
American Medical Association (AMA)
Shah, Dhruvil R.& Tseng, Warren H.& Martinez, Steve R.. Treatment Options for Metaplastic Breast Cancer. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-4.
https://search.emarefa.net/detail/BIM-492075
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-492075